ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.772,85
0,50%
S&P 500
5.222,68
0,16%
Dow Jones
39.512,84
0,32%
Euro vs US Dollar
1,07729
-0,14%
Bitcoin
61.189,36
0,64%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Hepion Pharmaceuticals Inc (HEPA)

  7. Hepion Pharmaceuticals Inc (HEPA) News

HEPA

Hepion Pharmaceuticals (HEPA)

Hepion Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:HEPA
DatumZeitQuelleÜberschriftSymbolFirma
19/04/202422h30GlobeNewswire Inc.Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ TrialNASDAQ:HEPAHepion Pharmaceuticals Inc
16/02/202415h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HEPAHepion Pharmaceuticals Inc
16/02/202414h00GlobeNewswire Inc.Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross ProceedsNASDAQ:HEPAHepion Pharmaceuticals Inc
14/02/202421h38Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:HEPAHepion Pharmaceuticals Inc
03/01/202423h15GlobeNewswire Inc.Hepion Pharmaceuticals to Present at NASH-TAG 2024NASDAQ:HEPAHepion Pharmaceuticals Inc
03/01/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HEPAHepion Pharmaceuticals Inc
07/12/202314h00GlobeNewswire Inc.Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management ChangesNASDAQ:HEPAHepion Pharmaceuticals Inc
28/11/202322h15GlobeNewswire Inc.Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development SummitNASDAQ:HEPAHepion Pharmaceuticals Inc
13/11/202322h05GlobeNewswire Inc.Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver DiseaseNASDAQ:HEPAHepion Pharmaceuticals Inc
10/11/202314h50GlobeNewswire Inc.Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of RencofilstatNASDAQ:HEPAHepion Pharmaceuticals Inc
09/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:HEPAHepion Pharmaceuticals Inc
25/10/202314h30GlobeNewswire Inc.Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer ModelNASDAQ:HEPAHepion Pharmaceuticals Inc
29/09/202314h00GlobeNewswire Inc.Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq RulesNASDAQ:HEPAHepion Pharmaceuticals Inc
21/09/202322h05GlobeNewswire Inc.Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare ConferenceNASDAQ:HEPAHepion Pharmaceuticals Inc
21/09/202314h00GlobeNewswire Inc.New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening ProgramNASDAQ:HEPAHepion Pharmaceuticals Inc
19/09/202315h00GlobeNewswire Inc.Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver CancerNASDAQ:HEPAHepion Pharmaceuticals Inc
18/09/202314h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HEPAHepion Pharmaceuticals Inc
14/09/202314h45GlobeNewswire Inc.Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary FibrosisNASDAQ:HEPAHepion Pharmaceuticals Inc
06/09/202322h40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HEPAHepion Pharmaceuticals Inc
06/09/202322h30GlobeNewswire Inc.Hepion Pharmaceuticals Announces Management ChangesNASDAQ:HEPAHepion Pharmaceuticals Inc
24/07/202322h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HEPAHepion Pharmaceuticals Inc
21/07/202322h41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HEPAHepion Pharmaceuticals Inc
21/07/202322h39Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:HEPAHepion Pharmaceuticals Inc
15/06/202322h45GlobeNewswire Inc.Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023NASDAQ:HEPAHepion Pharmaceuticals Inc
15/06/202314h22GlobeNewswire Inc.Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of RencofilstatNASDAQ:HEPAHepion Pharmaceuticals Inc
24/05/202322h45GlobeNewswire Inc.Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical SciencesNASDAQ:HEPAHepion Pharmaceuticals Inc
22/05/202313h00GlobeNewswire Inc.Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH BiomarkersNASDAQ:HEPAHepion Pharmaceuticals Inc
19/05/202322h05GlobeNewswire Inc.Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of RencofilstatNASDAQ:HEPAHepion Pharmaceuticals Inc
12/05/202322h19Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:HEPAHepion Pharmaceuticals Inc
10/05/202317h15GlobeNewswire Inc.Hepion Pharmaceuticals, Inc. Announces Reverse Stock SplitNASDAQ:HEPAHepion Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:HEPA

Kürzlich von Ihnen besucht

NASDAQ
KNSY
Kensey Nash
NYSE
MA
MasterCard
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten